Adaptive Biotechnologies
ADPT
$24.77
+0.12%
Adaptive Biotechnologies Corporation is a biotechnology company that leverages the adaptive immune system to develop diagnostic and therapeutic products, with its FDA-approved clonoSEQ test for minimal residual disease (MRD) detection in certain blood cancers as a key commercial asset. The company operates in two segments: Minimal Residual Disease (MRD) and Immune Medicine, positioning itself as a leader in immune-driven medicine with a proprietary platform that maps T-cell and B-cell receptors. The current investor narrative centers on the planned separation of its Immune Medicine segment, which analysts believe could unlock greater value by allowing the high-growth MRD business to be valued independently, while the stock has surged over 120% in the past year amid strong momentum and strategic repositioning.…
ADPT
Adaptive Biotechnologies
$24.77
ADPT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Adaptive Biotechnologies's 12-month outlook, with a consensus price target around $25.07 and implied upside of +1.2% versus the current price.
Average Target
$25.07
0 analysts
Implied Upside
+1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$21 - $28
Analyst target range
Adaptive Biotechnologies is covered by 7 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.5). The average price target is $23.86, implying a modest 5.7% upside from the current price of $22.57. The target range spans from $20.00 (low) to $28.00 (high), with the high target suggesting a 24% upside, likely reflecting optimism about the MRD segment's growth and the potential value unlock from the Immune Medicine separation. The relatively narrow spread between low and high targets (40%) indicates moderate conviction, though the strong buy consensus signals positive sentiment among analysts.
ADPT Technical Analysis
Adaptive Biotechnologies is in a powerful uptrend, with the stock price at $22.57 as of July 31, 2026, up 120.41% over the past year. The current price sits at 92% of its 52-week range (between $10.02 low and $24.568 high), indicating strong momentum and proximity to highs, which suggests bullish sentiment but also potential overextension. The stock has outperformed the S&P 500 significantly, with relative strength of 102.22% over the past year, confirming its leadership position.
Beta
2.09
2.09x market volatility
Max Drawdown
-39.4%
Largest decline past year
52-Week Range
$12-$26
Price range past year
Annual Return
+90.0%
Cumulative gain past year
| Period | ADPT Return | S&P 500 |
|---|---|---|
| 1m | +8.1% | +4.0% |
| 3m | +91.1% | +5.3% |
| 6m | +56.1% | +12.6% |
| 1y | +90.0% | +20.1% |
| ytd | +55.7% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ADPT Fundamental Analysis
Adaptive Biotechnologies has not yet achieved profitability, with a trailing EPS of -$0.024 and a net margin of -21.48% as of the latest data. However, the company's gross margin is strong at 74.24%, indicating a scalable business model, and operating margin is -20.62%, reflecting ongoing investment in R&D and commercialization. The company's revenue growth is not directly provided, but the estimated revenue for the next fiscal year is $676.1 million, suggesting a substantial top-line expansion from prior levels, driven by the MRD segment's growth.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ADPT Overvalued?
Given the negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 8.90x, which is a premium to the biotech industry average of around 5-6x. The EV-to-sales ratio is even higher at 12.72x, reflecting the market's premium for its growth potential. The forward PE is -108.72x, but the PEG ratio of 0.65 suggests that when factoring in expected earnings growth, the stock may be undervalued relative to its growth prospects.
PE
-41.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-89.6x
Enterprise Value Multiple